Seagen Inc.
Biological Products, (No Diagnostic Substances) · 21823 30TH DRIVE SE, SUITE, BOTHELL, WA 98021
官方登記資料
0位追蹤者
1997成立於
關於 Seagen Inc.
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, was considered the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells, with its development of drugs such as Adcetris, Padcev, and Tivdak. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
Source: Wikipedia
產業Biological Products, (No Diagnostic Substances)
總部21823 30TH DRIVE SE, SUITE, BOTHELL, WA 98021
成立時間1997
法律形式C Corporation
狀態營運中
專利889 項專利
ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESUS20260242481A1 · 2026
TREATING LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WITH ANTI-191P4D12 ANTIBODY DRUG CONJUGATES IN COMBINATION WITH PEMBROLIZUMABEP4780498A1 · 2026
關鍵數據
法律資訊
| 法定名稱 | Seagen Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1060736在 SEC EDGAR 上查看 ↗ |
| EIN | 91-1874389 |
| 產業代碼(SIC) | 2836 |
| 登記地址 | 21823 30TH DRIVE SE, SUITE, BOTHELL, WA 98021 |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日
聯絡方式與連結
地點
21823 30TH DRIVE SE, SUITE, BOTHELL, WA 98021
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面